192 related articles for article (PubMed ID: 29031905)
1. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
Braun LR; Feldpausch MN; Czerwonka N; Torriani M; Grinspoon SK; Stanley TL
Growth Horm IGF Res; 2017 Dec; 37():1-6. PubMed ID: 29031905
[TBL] [Abstract][Full Text] [Related]
2. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Stanley TL; Feldpausch MN; Oh J; Branch KL; Lee H; Torriani M; Grinspoon SK
JAMA; 2014 Jul 23-30; 312(4):380-9. PubMed ID: 25038357
[TBL] [Abstract][Full Text] [Related]
3. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Falutz J; Potvin D; Mamputu JC; Assaad H; Zoltowska M; Michaud SE; Berger D; Somero M; Moyle G; Brown S; Martorell C; Turner R; Grinspoon S
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):311-22. PubMed ID: 20101189
[TBL] [Abstract][Full Text] [Related]
4. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.
Stanley TL; Falutz J; Mamputu JC; Soulban G; Potvin D; Grinspoon SK
AIDS; 2011 Jun; 25(10):1281-8. PubMed ID: 21516030
[TBL] [Abstract][Full Text] [Related]
5. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S
J Clin Endocrinol Metab; 2010 Sep; 95(9):4291-304. PubMed ID: 20554713
[TBL] [Abstract][Full Text] [Related]
6. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
Stanley TL; Falutz J; Marsolais C; Morin J; Soulban G; Mamputu JC; Assaad H; Turner R; Grinspoon SK
Clin Infect Dis; 2012 Jun; 54(11):1642-51. PubMed ID: 22495074
[TBL] [Abstract][Full Text] [Related]
7. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.
Fourman LT; Czerwonka N; Feldpausch MN; Weiss J; Mamputu JC; Falutz J; Morin J; Marsolais C; Stanley TL; Grinspoon SK
AIDS; 2017 Oct; 31(16):2253-2259. PubMed ID: 28832410
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J; Allas S; Blot K; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
N Engl J Med; 2007 Dec; 357(23):2359-70. PubMed ID: 18057338
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Mangili A; Falutz J; Mamputu JC; Stepanians M; Hayward B
PLoS One; 2015; 10(10):e0140358. PubMed ID: 26457580
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
Makimura H; Feldpausch MN; Rope AM; Hemphill LC; Torriani M; Lee H; Grinspoon SK
J Clin Endocrinol Metab; 2012 Dec; 97(12):4769-79. PubMed ID: 23015655
[TBL] [Abstract][Full Text] [Related]
11. Tesamorelin improves fat quality independent of changes in fat quantity.
Lake JE; La K; Erlandson KM; Adrian S; Yenokyan G; Scherzinger A; Dubé MP; Stanley T; Grinspoon S; Falutz J; Mamputu JC; Marsolais C; McComsey GA; Brown TT
AIDS; 2021 Jul; 35(9):1395-1402. PubMed ID: 33756511
[TBL] [Abstract][Full Text] [Related]
12. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.
Adrian S; Scherzinger A; Sanyal A; Lake JE; Falutz J; Dubé MP; Stanley T; Grinspoon S; Mamputu JC; Marsolais C; Brown TT; Erlandson KM
J Frailty Aging; 2019; 8(3):154-159. PubMed ID: 31237318
[TBL] [Abstract][Full Text] [Related]
13. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Stanley TL; Fourman LT; Feldpausch MN; Purdy J; Zheng I; Pan CS; Aepfelbacher J; Buckless C; Tsao A; Kellogg A; Branch K; Lee H; Liu CY; Corey KE; Chung RT; Torriani M; Kleiner DE; Hadigan CM; Grinspoon SK
Lancet HIV; 2019 Dec; 6(12):e821-e830. PubMed ID: 31611038
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Falutz J; Allas S; Mamputu JC; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
AIDS; 2008 Sep; 22(14):1719-28. PubMed ID: 18690162
[TBL] [Abstract][Full Text] [Related]
15. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.
Stanley TL; Chen CY; Branch KL; Makimura H; Grinspoon SK
J Clin Endocrinol Metab; 2011 Jan; 96(1):150-8. PubMed ID: 20943777
[TBL] [Abstract][Full Text] [Related]
16. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Fourman LT; Billingsley JM; Agyapong G; Ho Sui SJ; Feldpausch MN; Purdy J; Zheng I; Pan CS; Corey KE; Torriani M; Kleiner DE; Hadigan CM; Stanley TL; Chung RT; Grinspoon SK
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701508
[TBL] [Abstract][Full Text] [Related]
17. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
18. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.
Fourman LT; Stanley TL; Billingsley JM; Sui SJH; Feldpausch MN; Boutin A; Zheng I; McClure CM; Corey KE; Torriani M; Kleiner DE; Hadigan CM; Chung RT; Grinspoon SK
Sci Rep; 2021 May; 11(1):10485. PubMed ID: 34006921
[TBL] [Abstract][Full Text] [Related]
19. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
Makimura H; Murphy CA; Feldpausch MN; Grinspoon SK
J Clin Endocrinol Metab; 2014 Jan; 99(1):338-43. PubMed ID: 24178787
[TBL] [Abstract][Full Text] [Related]
20. Reduction in serum fibroblast growth factor-21 after gastric bypass is related to changes in hepatic fat content.
Fjeldborg K; Pedersen SB; Møller HJ; Richelsen B
Surg Obes Relat Dis; 2017 Sep; 13(9):1515-1523. PubMed ID: 28552744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
